N/A N=439 Comparison of DSM-IV-TR and DSM-5 for ASD
Autism Spectrum Disorder
Primary: Clinical Features of Concordant vs Discordant Groups — 76.18; 89.85; 14.96; 13.94 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
Overactive Detrusor
Primary: Mean Peak Detrusor Pressures — 58; 31 cm H2O
Phase 2 N=47 Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Area Under the Curve — 271; 537; 341; 324 ng/ml x hr
Phase 3 N=281 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Basal Cell Carcinoma (BCC)
Primary: Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT — 93.4; 91.8 Percentage of Patients — p=<0.0001
N/A N=11 Use of the Passy Muir Swallowing Self Trainer
Stroke · Brain Injury · Head and Neck Cancer
Primary: Change in Dysphagia Outcome and Severity Scale (DOSS) Rating — 5; 2 Participants — p=<0.025
N/A N=214 Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART
HIV Infection
Primary: Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups — 0.19; 0.09 percent change…
Phase 1 N=15 A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations — 0.27; 0.17 micromole per Liter (μmol/L)
N/A N=22 Reducing Children's Anxiety Using Homeopathic Remedy Before Dental Treatment
Children's Dental Anxiety
Primary: Reducing Children's Anxiety — 1.38; 2.28; 1.39; 4.37 ng/ml
Phase 3 N=157 Varenicline for Adolescent Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment — 4; 4 Participants
N/A N=240 Comparison of Treatments Following Total Knee Replacement
Degeneration; Articular Cartilage, Knee · Rheumatoid Arthritis · Osteoarthritis, Knee
Primary: The Western Ontario and McMaster Universities Osteoarthritis Index Physical Function (WOMAC-PF). — 20.9; 20.4; 20.2; 10.1 units on a scale — p=0.071
Phase 1 N=28 A Study of the Effect of LY2216684 on Lorazepam
Major Depressive Disorder
Primary: Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax) — 9.620; 10.720 nanograms per milliliter (ng/mL)
Phase 1 N=35 A Study of LY2409021 Formulations and the Effect of Food
Healthy Volunteers
Primary: Pharmacokinetics, Area Under the Concentration-Time Curve (AUC): Medium Test Form to Reference Form — 65300; 62800 nanograms*hour per milliliter (ng*hr/mL)
Phase 1 N=8 Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
Anaemia
Primary: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites — 184.9863; 138.6511; 162.9366; 131.2826 Hour into…
Phase 2 N=24 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Sarcoma
Primary: Part 1: Incidence of Dose Limiting Toxicities — 1; 4; 3 participants
N/A N=92 Torsion of the Tibial Tuberosity, a New Factor of Patellar Instability?
Patellar Instability · Patellar Dislocation
Primary: Existence of Tibial Tuberosity Torsion. — 17.5; 5.3 degre